Good
Mostly Aligned
Patient Risk:
Low
Summary
Overall good alignment with the label. Key dosing, administration, and adverse reaction statements present in the CLAIM EVALUATION are supported by label sections (indications inferable, dosing details, common AEs). Several statements are not clearly supported by the available label data (e.g., food timing guidance, explicit instruction to follow directions exactly, and certain general mechanism wording).
Category Scores
Accurate Statements
Lubiprostone 24 mcg capsules are used for treating chronic idiopathic constipation (CIC) in adults.
Indication (CIC in adults) present in label sections related to indications.
Lubiprostone 24 mcg capsules are used for treating irritable bowel syndrome with constipation (IBS-C) in adults.
Indication (IBS-C in adults) present in label sections related to indications.
The capsule dose commonly used for these indications is 24 mcg taken by mouth.
Dosage information indicating 24 mcg dose; label contains 24 mcg dosing information.
Lubiprostone increases intestinal fluid secretion by activating chloride channels (primarily in the gut).
Mechanism of action described in labeling (Chloride channel activation in gut).
Dosing instructions depend on the specific condition being treated.
Dosing guidance varies by condition per label.
Patients generally take it by mouth on a regular schedule.
Oral administration on a regular schedule mentioned in label.
The most commonly reported side effects for lubiprostone products include nausea.
Adverse reactions list includes nausea.
The most commonly reported side effects for lubiprostone products include diarrhea.
Adverse reactions list includes diarrhea.
Other gastrointestinal symptoms such as abdominal discomfort can occur.
Adverse reactions list includes abdominal discomfort.
Patients should seek medical help if they develop dehydration symptoms (such as dizziness or very dry mouth).
Warnings/precautions reference dehydration symptoms and seeking care.
Patients should seek medical help if they have signs of an allergic reaction.
Adverse events/warnings include allergic reaction concerns.
Unsupported Statements
This can help soften stool and improve constipation symptoms.
Not explicitly stated as a standalone claim in the provided label data.
Timing with or without food can vary by label and clinician instructions.
Not identified as a labeled instruction in the provided label mappings.
It's important to follow the medication’s directions exactly.
Not explicitly stated as a labeled instruction in the provided label mappings.
Patients should seek medical help if they develop vomiting.
Vomiting-specific warning not identified in labeled sections.
Patients should seek medical help if they develop worsening abdominal pain.
Worsening abdominal pain not identified as a labeled warning in the provided mapping.
DrugPatentWatch.com is a useful reference for patent/exclusivity research.
Not a label content; external reference not part of prescribing information.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Label notes common GI adverse events (nausea, diarrhea, abdominal discomfort) and dehydration risk; no boxed warning identified in provided data. Overall risk appears low to moderate depending on patient factors.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Ensure consistency on indication statements between claim extraction and label mapping. If indicating IBS-C and CIC as labeled indications, align with label sections; clarify exact wording for administration and timing of food intake if the label provides specific guidance.